Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Bluebird bio presents phase I/II data on LentiGlobin for sickle cell disease

Feb. 25, 2020

Phase IIb results presented for dalcinonacog alfa in hemophilia B patients

Feb. 12, 2020

AMT-060 gene therapy provides long-term factor IX activity in hemophilia B patients

Feb. 10, 2020

Thrombosis leads to early termination of phase II BAY-1093884 trial

Feb. 10, 2020

First-in-human data show safety and early hemostatic efficacy of BAY-2599023

Feb. 10, 2020

Verseon divulges new thrombin inhibitors

Feb. 4, 2020

Initial first-in-human data presented for OTL-102

Feb. 4, 2020

Bayer presents data from the phase II FOXTROT study of osocimab

Feb. 3, 2020

Janssen presents phase II results for daratumumab in relapsed AL amyloidosis

Jan. 29, 2020

Results from phase I/II COMPOSER study of crovalimab

Jan. 29, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 7, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 7, 2024.
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...
Sanofi bets on Resalis’ oligonucleotide RES-010 for obesity
BioWorld
After missing out on the glucagon-like peptide 1 obesity market, Sanofi SA is prospecting for next-generation drugs and is making a strategic equity investment in...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.